Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cullinan Therapeutics Inc (NQ: CGEM ) 16.71 -0.20 (-1.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cullinan Therapeutics Inc < Previous 1 2 3 4 Next > Cullinan Oncology to Participate in Upcoming Investor Conferences February 27, 2024 From Cullinan Oncology, Inc. Via GlobeNewswire Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket January 30, 2024 Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter. Via Benzinga Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Recap: Cullinan Oncology Q3 Earnings November 08, 2023 Via Benzinga Analyst Ratings for Cullinan Oncology August 09, 2023 Via Benzinga Analyst Ratings for Cullinan Oncology July 07, 2023 Via Benzinga Analyst Expectations for Cullinan Oncology's Future June 15, 2023 Via Benzinga Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines December 14, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 08, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 November 03, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Expert Ratings for Cullinan Oncology June 15, 2023 Via Benzinga 4 Analysts Have This to Say About Cullinan Oncology May 26, 2023 Via Benzinga A Look Into Healthcare Sector Value Stocks May 22, 2023 Via Benzinga Cullinan Oncology to Participate in Upcoming Investor Conferences October 30, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 October 06, 2023 Via Benzinga Overview Of Value Stocks In The Healthcare Sector April 10, 2023 Via Benzinga What 4 Analyst Ratings Have To Say About Cullinan Oncology March 27, 2023 Via Benzinga Cullinan Oncology to Participate in Upcoming Investor Conferences September 06, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results August 10, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma August 09, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology to Participate in Upcoming Investor Conferences July 31, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 June 15, 2023 Via Benzinga Why Shares of Cullinan Oncology Jumped This Week June 09, 2023 The company's presentation at a conference got the attention of analysts and investors. Via The Motley Fool Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 May 25, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results May 11, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 April 26, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days April 20, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines March 27, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting March 14, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results March 09, 2023 From Cullinan Oncology, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.